#	Pagina
attuale pagina	/open-h2020/projects/197050/index.html
-1	/open-h2020/projects/198850/index.html
-2	/open-h2020/projects/221887/index.html
-3	/open-h2020/per-topic/superbug/list/index.html
-4	/open-h2020/projects/196563/index.html
-5	/open-h2020/projects/217304/index.html
-6	/open-h2020/projects/219251/index.html
-7	/open-h2020/projects/225124/index.html
-8	/open-h2020/projects/224276/index.html
-9	/open-h2020/projects/204402/index.html
-10	/open-consip/fornitori/2015/profilo-01524200225/index.html

Opendata, web and dolomites

ProCanEx

Prostate cancer diagnostic assay based on protein kinase activity profiling in exosomes

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

ProCanEx project word cloud

Explore the words cloud of the ProCanEx project. It provides you a very rough idea of what is the project "ProCanEx" about.

circulating billion innovation practical disease europeans healthcare originating annually men strategy plan health business tests 70 totalled diagnostic specificity market complementary exosome unnecessary profiling innovative 12 protein invasive biomarker covered treatment measuring detection diagnosed platform quantitative patient debated sources diagnostics 2012 mainly supports deadliest age 417 discovered instrument usd altered diseases positive 2017 prostate technological exosomes composition decisions tissue antigen assay sustainability sme care kinases painful levels worldwide licensee cancer markers screening 17 scientific combines positives stratification literature prognosis biopsies newly 45 psa clinical practicality pca performed diagnosis million probes sought false financing

Project "ProCanEx" data sheet

The following table provides information about the project.

Coordinator	KINASERA OU Organization address address: UUS 63-55 city: TARTU postcode: 50606 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Estonia [EE]
Project website	http://www.kinasera.com
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2015
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-06-01 to 2015-11-30

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	KINASERA OU KINASERA OU Organization address address: UUS 63-55 city: TARTU postcode: 50606 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	EE (TARTU)	coordinator	50˙000.00

Map

Project objective

The objective of the innovation project is the development of novel biomarker-based non-invasive assay for prostate cancer (PCa) detection. 417 000 Europeans were diagnosed with PCa in 2012, about 12% of all new cancer cases of European men. The diagnosis and screening of PCa totalled 12 billion USD in 2012 and will reach 17.4 billion USD in 2017 since the PSA test is performed for men over 50 years of age annually. The PCa diagnostics market is mainly covered by the Prostate-Specific Antigen (PSA) test, the practicality of which is debated. The low specificity of the test means a high number of false positives, leading to unnecessary and painful procedures (biopsies, treatment, etc.). More than 45 million PSA tests are performed annually worldwide, while more than 9 million of those are positive, with around 70% false positives. Our assay is built on an innovative technological platform based on quantitative profiling of protein kinases in circulating exosomes. Recent scientific literature supports the potential of exosomes as diagnostic markers. Our assay combines two innovative approaches - newly discovered changes in exosome composition in cancer and probes for measuring altered levels of several protein kinases in exosomes originating from the cancer tissue. We will use the phase I of the SME instrument to make a detailed business plan, market research and evaluate technological, technical and practical issues. Collaboration with a potential licensee and complementary sources of financing for Phase II are sought. A detailed research plan will be conducted. Cancer diagnostics is among the main concerns for healthcare as cancer is among the deadliest diseases. Our proposal aims at development of innovative, non-invasive, highly reliable and cost-effective test for PCa, which would contribute to the sustainability of European health care system. Our strategy will enable patient stratification and/or prognosis of disease leading to the improved clinical decisions.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PROCANEX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PROCANEX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development